ACC 2023 | A DUE-Study (Phase III)

In pulmonary hypertension (PHT), 10 mg macitentan plus 40 mg tadalafil is recommended as a safe combination therapy for newly diagnosed patients or in a significant proportion of patients during follow-up. Using a tablet with a fixed drug combination (FDC) could simplify treatment.

ACC 2023 | A DUE-Study (Fase III)

The aim of this study was to evaluate the efficacy and safety of macitentan/tadalafil in FDC vs. macitentan and tadalafil monotherapy in patients with PHT. It was a randomized, prospective, multicenter, double-blind, phase III study, with a 16-week follow-up.

The study included patients who were treatment-free or who had stable doses of endothelin receptor antagonists or stable doses of phosphodiesterase-5 inhibitors, with a subsequent 1:2 randomization to macitentan 10 mg, macitentan/tadalafil, or tadalafil 40 mg. 

Efficacy outcomes were studied at 16 weeks. The primary endpoint was change in pulmonary vascular resistance (PVR) from baseline. The secondary endpoint was change in the 6-minute walk test (6MWT). The safety and tolerability of the treatment were also evaluated.

Read also: ACC 2023 | Ultrasensitive Troponin I Monitoring with a Transdermal Wrist Device.

The study enrolled 187 randomized patients. The combination in FDC decreased PVR by 45% from baseline, in contrast to macitentan, which decreased it by 23% (mean ratio: 0.71: 95% confidence interval [CI]: 0.71-0.82; p ≤ 0.0001). When compared with tadalafil, the difference in pulmonary resistance was 28% better (average ratio: 0.72, 95% CI: 0.64-0.80; p ≤ 0.0001). However, there was a nonsignificant difference from baseline when analyzing the 6MWT (p = 0.380).

Conclusions: The combination of macitentan and tadalafil at fixed doses significantly decreased (28%) pulmonary vascular resistance.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: “Efficacy And Safety Of Macitentan Tadalafil Fixed Dose Combination In Pulmonary Arterial Hypertension: Results From The Randomized Controlled Phase III A DUE Study”.

Reference: Presentado por Kelly Chin en Late Breaking Trials del ACC.23/WCC Marzo 4-6, 2023, en New Orleans.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....